Cancer Treatment and Prevention

Pauline Latham Excerpts

Tuesday 11th March 2014 Westminster Hall

Motion made, and Question proposed, That the sitting be now adjourned.—(Mark Lancaster.)

[Pauline Latham (Mid Derbyshire) (Con)]

It is a delight to serve under your chairmanship today, Mr Gray.

During the past few months, cancer has been something of a hot topic in this House, and the Government have committed themselves to reducing the number of people who die from cancer every year. That is an admirable goal and the provision of services to cancer patients has undoubtedly improved. However, the complicated licensing procedure for cancer drugs and the lack of knowledgeable doctors are preventing patients from receiving the life-saving treatment they need.

During my tenure as an MP, I have had the privilege of working with a cancer charity called Melanoma UK. Melanoma is a cancer that is particularly close to my heart, as my brother died from a malignant melanoma when he was only 54. What is most insidious about this cancer is that it is impossible to treat in its late stages, and it often results in a drawn-out and painful death for the sufferer.

Last week, I sat in on a meeting of the Melanoma Taskforce, which is attended by experts in skin cancer, patients and their families. The consistent theme of the complaints from these experts was that initial diagnosis and referrals of potential melanoma sufferers were taking too long, which often results in sufferers receiving treatment that comes too late to save their lives. In the case of my brother, he went to the doctor three times, but the doctor said, “There is absolutely nothing wrong with you.” Eventually, he told my brother, “All right, I will refer you to Addenbrooke’s and you can go and see somebody, but I’m sure it’s fine”, by which time more than a year had passed and it was far too late.

As I say, the consistent theme of the experts’ complaints was that initial diagnosis and referrals of potential melanoma sufferers take too long, which often results in sufferers receiving treatment that comes too late to save their lives. At that meeting, I learned that medical students receive only a week or less of teaching on dermatology, and that is on the whole of dermatology, not just melanomas. Even less time was spent on teaching them how to spot the signs and symptoms of melanoma. All that is shocking, given that malignant melanoma is the fifth most common cancer in the UK.

Another piece of feedback that I received from the dermatologists who were present at that meeting is that there are simply not enough consultants in this field and the few dermatologists that there are end up being completely inundated with patients. Sadly, the figures fully support that opinion: there are only 650 dermatology consultants practising nationwide. How can so few consultants effectively deal with the influx of potential melanoma referrals? Given this state of affairs, it is imperative that the Department of Health and the UK’s teaching hospitals encourage medical students to pursue a career in dermatology.

The other bar to the survival of late-stage melanoma patients is the difficulty in accessing effective cancer drugs. As some Members may know, about two weeks ago the National Institute for Health and Care Excellence published its response to the consultation on the use of the drug ipilimumab as the first-line treatment for late-stage melanoma. Currently, the drug that is prescribed in the first instance is dacarbazine, which is generally acknowledged to be ineffective in fighting the progression of the disease. On the other hand, ipilimumab has been proven to extend people’s lives and give them a better quality of life during treatment.

One case study to recommend ipilimumab as a first-line treatment is the story of Richard Jackson, who was told that he had only weeks to live when he was diagnosed with late-stage melanoma and was prescribed the drug straight away. As a consequence of the early prescription of ipilimumab, Richard is still alive seven years after being diagnosed with melanoma. When one considers that, when he was given the diagnosis, he was planning his funeral, because he was told that he had only weeks or months to live, that is remarkable.

Dacarbazine, which is a type of chemotherapy, often leaves patients sicker than before they began using it, and they are generally progressed on to ipilimumab anyway. NICE’s decision was based on a number of factors, including cost. If the majority of patients do not benefit from dacarbazine as a first-line treatment, NICE’s decision not to use ipilimumab initially both fails to provide value in the long term for the British taxpayer and shortens people’s lives.

With that in mind, I call upon the Department of Health to make melanoma a real priority. I know that everybody wants everything to be a “real priority”, so I understand the Department’s difficulties in that respect, but melanoma can be cured if it is detected early. The Department needs to start by motivating young doctors to study dermatology, and by working with universities so that the time devoted to teaching this important subject can be extended. Most urgent, however, is the need for the Department to put pressure on NICE to offer ipilimumab as a first-line treatment to extend the life expectancy of melanoma sufferers and—perhaps vitally—improve their quality of life, so that they can continue to contribute to society for longer as well as having a better quality of life.

Ongoing changes to the UK cancer infrastructure, such as downsizing and dismantling the cancer networks in April 2013 and the National Cancer Action Team being merged into NHS Improving Quality, risk creating a gap in the cancer expertise that is used to advise and shape the NHS and the Department of Health. NHS England is looking to broaden its work in other disease areas beyond cancer. The cancer policy team at the Department has been all but abolished, with just a handful of its staff remaining. This inevitably dilutes the cancer expertise in the Department.

The overall reduction in expertise and resource in oncology will limit the ability to identify and spread best practice and drive innovation in treatment and care. Although the diversion of resources and expertise away from cancer is worrying, it is positive to see a strong policy focus on preventing people from dying prematurely, through domain 1 of the NHS outcomes framework.

Each clinical commissioning group should have at least one member with an interest in cancer. Previously, GPs benefited from better liaison with specialists via the cancer networks, and they could use the lessons learned from that approach and build on them further to create informal communities of primary and secondary care colleagues interested in cancer, to influence what is happening in CCGs.

Multidisciplinary teams for cancer should work to feed into strategic clinical networks, in the way that they previously worked with the cancer networks, to promote collaboration, consistency and quality of care. National clinical advisory groups for the common cancers should be re-established to bolster the work of strategic clinical networks in sharing best practice, supporting intelligent commissioning and driving up standards of care.

The extension of the Cancer Drugs Fund is welcome, but there is now a need for long-term clarity that, after 2016, the new pricing and reimbursement scheme will offer patients an appropriate level of access to cancer drugs that have been proven to be effective. Furthermore, we must collect better data on what medicines cancer patients across the UK need. It is also essential that NICE offers flexibility in its appraisal of cancer medicines. It should consider looking at cancer treatments under its own separate criteria, in particular measures beyond overall survival.

The Government have done a lot of good work on cancer, but there is still more to do. I am particularly interested in melanomas and bowel cancer; they are the two cancers that I tend to specialise in. There is more work to do on those cancers, and success is about early diagnosis. If we can get early diagnosis and appropriate treatment, the Government will succeed in achieving the aim of giving people longer life and better quality of life.

Oral Answers to Questions

Pauline Latham Excerpts

Tuesday 25th February 2014 Commons Chamber

[The Parliamentary Under-Secretary of State for Health (Dr Daniel Poulter)]

I would like to point out to the hon. Lady that it is not unusual for doctors in training to work overseas to improve their medical experience. Many of my contemporaries did that, and every one I know has returned to work in the NHS in the UK. It is a common phenomenon that benefits doctors’ experience. What we have done, unlike the previous Government, is ensure that we now have a 100% fill rate for people entering A and E common stem training.

[Pauline Latham (Mid Derbyshire) (Con)]

T6. What assessment have the Government made of the decision by the National Institute for Health and Clinical Excellence not to recommend ipilimumab as a first-line treatment for advanced melanoma, except in clinical trials? Will the Minister join me in calling on NICE to reverse this decision and ensure that patients receive earlier access to this treatment to improve their chances of survival?

[The Parliamentary Under-Secretary of State for Health (Jane Ellison)]

I know that my hon. Friend is really concerned about this, but NICE is an independent body so it would not be appropriate for me to interfere in an ongoing appraisal. NICE has recommended a number of other treatments for advanced melanoma, and NHS commissioners are required to fund them where clinicians want to use them. I want to give her some encouragement: this spring a trial will begin of an awareness programme on melanoma in the south-west of England, working with Cancer Research UK.

Cancer Priorities

Pauline Latham Excerpts

Thursday 13th February 2014 Commons Chamber

[Pauline Latham (Mid Derbyshire) (Con)]

I am delighted to be able to speak on this matter today and congratulate my hon. Friend the Member for Basildon and Billericay (Mr Baron) on securing the debate and the Backbench Business Committee on allowing it to happen. We would have had many more Members contributing to this debate if it were not on a Thursday afternoon immediately before a recess. Many Members also have problems getting home because of disrupted transport and, when they get there, they have to face flooding issues. It is disappointing that this debate was not scheduled for a much more popular time.

I also pay tribute to the hon. Member for Ashton-under-Lyne (David Heyes) for coming to talk about his personal experiences, which must have been very difficult. I am pleased to see that he is fit and well—or appears to be—and delighted that he is in the Chamber today. Like many Members, I have been affected by cancer, but not personally. A number of members of my family have unfortunately died at very young ages from various forms of the disease. I take a great interest in what happens to people who are either diagnosed with it or who have various issues with it.

One type of cancer that is particularly close to my heart is melanoma, having lost my brother to the disease 13 years ago. In 2011, more than 11,000 people were diagnosed with melanoma. It is a type of cancer that is relatively easily treatable if it is caught early. Simply removing the affected tissue can usually cure the disease. Given that it is easily treatable in its early stages, it is shocking that 11 % of those diagnosed die within the first five years. These figures would surely imply that there is a problem with awareness of the symptoms of the disease, and, as a consequence, with how long it takes patients to be diagnosed. Doctors need to get better at it. As the hon. Gentleman said, it often takes three visits to a GP before referral to a specialist. My brother went to his GP three times in a year before the GP suddenly said, “Well, there is nothing really wrong with you, but I will refer you,” By that time, it was far too late, and he died of a melanoma a few years later.

I note that the APPG’s excellent report recommends that the current advertising campaigns should continue and I am very pleased that an advertising campaign about melanoma will start in May 2014. Although preventing skin cancer is vital, the focus of the campaign should be on identifying its symptoms because, as lay people, most of us do not know what to look out for. I met one consultant who used to work in Australia, who told me that Australian school children go to school with rucksacks on their backs to take their books and kit to and from school and on each side are mesh holders, one for water and one for sun cream. We must encourage that practice in the UK, and teachers must not be frightened to help young people apply the cream in case they are labelled paedophiles. That is complete nonsense and they need to get over it and help young children who cannot apply the cream themselves.

Through my involvement with the charity Melanoma UK, I know that five-year survival rates are hampered by NICE guidelines on the treatment available to late-stage melanoma sufferers. The first line of treatment offered to patients is dacarbazine, which is generally accepted by clinicians as insufficient to treat late-stage melanoma. There is a call for NICE to recommend a second-line treatment, ipilimumab or Yervoy, in the first instance rather than dacarbazine and I believe that NICE is consulting on that.

One study that recommends ipilimumab as a first-line treatment concerns a man named Richard Jackson, who was told that he had only weeks to live when he was diagnosed. He was deciding which hymns to have at his funeral, but when he went to his doctor he decided to give him ipilimumab straight away. As a consequence of the early prescription of ipilimumab, Richard is still alive seven years after diagnosis. It does not make economic sense to use a first-line drug with such a low success rate only, in the majority of cases, to progress the patient on to ipilimumab when they are much weakened by the first drug. That gives them much less chance of doing well. Given the Government’s commitment to fighting cancer, I think it is important that pressure should be brought to bear on NICE to ensure that ipilimumab is available in the first instance. This debate is timely, because NICE is considering the issue right now.

One type of cancer that has been part of a successful national advertising campaign is, of course, bowel cancer. Perhaps Members will remember that when we had not been here for long after the 2010 election one Member wore a tie that contained a musical device that played a tune and it went off. That probably did more to raise awareness of bowel cancer than any other event. Although the Be Clear on Cancer campaign has no doubt been helpful in fighting bowel cancer, it remains to be seen whether its effects have been positive, as the results of the national cancer audit are due to be published later this year. In the interim, I welcome the APPG’s suggestion that the advertising campaign should be extended, as it will undoubtedly lead to more people being diagnosed with bowel cancer earlier.

People do not like talking about their bowels, but they should. They should not be nervous or embarrassed about it, because if they talk about things, they might realise that their symptoms are the very symptoms that are causing problems for so many people. I speak about this from personal experience because three members of my family have died of that cancer between the ages of 51 and 54, and one at 66. That is incredibly young these days. It is such a deadly disease unless, like others, it is caught early. Then, it is curable.

Although there is no mention of cancer drugs in the report, one element of cancer care that particularly concerns me is the legacy of the cancer drugs fund and what will happen to the provision of cancer drugs after its closure in 2016. The east midlands cancer drugs fund closed in 2013, and in every year of its existence it was left with lots of money to spare at the end of the financial year. One constituent of mine, Jill Bilbie, contacted me when she was funding her own treatment for cancer. It did not matter what I said or did, I could not persuade the cancer drugs fund to pay for the Avastin she so desperately needed even when it had the funding. All the fund said was that Avastin did not work, but she survived for three years on something that did not work. Sadly, she has now died, but during her illness, she paid more than £31,000 for the drugs, and people should not have to do that. It goes without saying that the cancer drugs fund and whatever replaces it in 2016 must be more flexible to the requirements of those making funding applications for drugs and must prevent the situation whereby desperate people exhaust their limited finances to fund their treatment.

Selective internal radiation therapy involving spheres is another cancer therapy that my constituents have had difficulty obtaining on the NHS. I was contacted by a constituent, Kate, who I had known for many years, who had been diagnosed with colorectal liver metastases and was trying to get that therapy to reduce the progress of the disease in her liver. As the cancer had metastasised from the primary tumour in her colon, she was refused. Once again, the guidelines for that particular treatment are insufficiently flexible and lead to premature mortality in otherwise treatable cancers. Another of my constituents managed to get the treatment not because the NHS funded it, but because she had private medical insurance. She is still alive today, which shows that the treatment works, so people should be able to get it. I am disappointed that, regarding the treatments that my constituents can get, the east midlands is a poor relation in comparison with other areas.

I generally agree with the report’s findings. A lot of effort went into the report, so I congratulate my hon. Friend the Member for Basildon and Billericay, who puts in a lot of work on the subject all the time, on bringing it forward. There must be an emphasis on the early detection of cancer, but I am worried that not enough is being done to ensure that cancer patients get the right treatment at the right time. I am pleased that the Government are aiming to reduce the number of cancer deaths every year by 5,000, but that aim is less likely to succeed if the Department of Health does not deal with early diagnosis.

Joint Committee on Vaccination and Immunisation

Pauline Latham Excerpts

Wednesday 8th January 2014 Westminster Hall

[Pauline Latham (Mid Derbyshire) (Con)]

It is a delight to serve under your chairmanship, Mr Gray. I congratulate my hon. Friend the Member for Finchley and Golders Green (Mike Freer) on securing this important debate.

I wish to change the subject and address meningitis B. A vaccine is available, and the Minister and the Department have decided that it is not cost-effective. I wonder what costs they have taken into account. Was it the lifelong costs of looking after a child such as my constituent Isabelle, who contracted meningitis B when she was seven years old? Isabelle was given a 0.7% chance of survival. She survived, but she had to have both her arms and both her legs amputated. She is the most amazing little girl. She is so bubbly, so bright and so cheerful given what she has to deal with, but there is the cost to the NHS, the cost of education and the cost of continuing care for the rest of her life—she is now 10 years old. She has to have four sets of legs and two sets of arms, which change regularly and cost thousands of pounds each. She has to have two wheelchairs, one portable and one mechanical, because she cannot walk far.

Isabelle has to have continuing care in school. Someone has to sit with her in classes because, clearly, there are things that she cannot do. She cannot easily carry her books from class to class, for instance, and she will need such care not just for the rest of her school and university life but for the rest of her working life, because she will be limited in what she is able to do.

Isabelle is the most amazing child that I have ever come across. She has come through such terrible circumstances. Her family had to make the awful decision that both her legs and both her arms had to be amputated. No parent should have to make that decision, and no child should have to live with that consequence for the rest of their life. She is not the only such child in this country; there are a lot of children in that situation with varying degrees of disability.

When the Minister reconsiders universal vaccination, will she bear it in mind that, although it is expensive, the emotional costs of what Isabelle’s family went through outweigh that expense? The Minister should consider the matter in the round, not just the cost to the NHS of vaccinating every child. We should consider what vaccination is doing for the whole country in saving money and preventing parents from having to make such a terrible decision. It must have been agony for the parents, the child and the family to survive in that situation. Will the Minister reconsider what can be done to ensure universal vaccination against meningitis B?

Oral Answers to Questions

Pauline Latham Excerpts

Tuesday 11th June 2013 Commons Chamber

[Dr Poulter]

I would be delighted to do so.

[Pauline Latham (Mid Derbyshire) (Con)]

14. What recent assessment he has made of the national cancer drugs fund list.

[The Minister of State, Department of Health (Norman Lamb)]

In April 2013, NHS England published a national list of drugs available from the fund. The list was updated recently following a meeting of the national cancer drugs fund clinical panel. Clinicians can apply to the fund for the inclusion of a drug within the approved list.

[Pauline Latham]

The cancer drugs fund is due to come to an end in less than a year. Given that more than 28,000 patients have received treatment since the CDF was introduced, what discussions has the Minister had with NHS England on continuing funding for it after the end of the current arrangements?

[Norman Lamb]

My hon. Friend has campaigned vigorously to ensure that as many people as possible get access to the drugs they need. The fund has been a great success. More than 30,000 have I think now benefited from it. We want to do all we can to ensure that the good lessons we have learned from it continue.

Health and Social Care

Pauline Latham Excerpts

Monday 13th May 2013 Commons Chamber

[Pauline Latham (Mid Derbyshire) (Con)]

It is a pleasure to speak in the health and social care debate on the Queen’s Speech, which seems to have been rather wide-ranging.

I pay tribute to the Government for introducing the Care Bill. It shows that they have listened to the concerns of many people. I support the proposals for three main reasons. First, the Bill will put people in control of their care and give them greater choice. Secondly, it will simplify the system and processes to provide the freedom and flexibility that local authorities and social workers need to innovate and achieve better results. Thirdly, it will provide people with a better understanding of what is on offer, help them to plan for the future, and ensure that they know where to go for help when they need it.

The Care Bill is essential to the modernisation of adult care and support in England. One purpose of the Bill is to set out clearly what support people can expect from the Government and what action the Government will take to help them to plan, prepare and make informed choices about their care. I support the well-being principle as an underlying principle for care and the support for carers. However, I urge colleagues in the Department of Health to monitor the implementation of the Bill carefully to ensure that local authorities are completely clear about their responsibilities.

I have a constituent who suffers from an acquired brain injury. His parents sought assistance from the adult care services department of their local authority, Derby city council, and from the primary care trust. Both organisations say that it is the other’s responsibility. That is causing great distress and frustration to my constituent’s elderly parents who are caring for him and his six-year-old child. I have written to both parties, as well as to Ministers in the Department of Health, and so far both have repeatedly refused to take responsibility.

I have also written to Health Ministers about another constituency case. A constituent of mine is suffering from severe chronic pancreatitis and has been told he needs to undergo a pancreatectomy and an islet cell transplant. However, as the national specialised commissioning group has not issued confirmation of funding for an islet cell laboratory in my region, my constituent is left suffering in extreme pain unnecessarily. I would like to see movement on the two cases that I have raised with the Department of Health.

Over the past three years, I have also raised constituency casework concerning the cancer drugs fund, and I pay tribute to my right hon. Friend the Prime Minister who set up that initiative. Some 23,000 cancer patients in England have benefited from the additional £650 million provided by the Government to fund cancer drugs.

[Mel Stride (Central Devon) (Con)]

Like my hon. Friend, I welcome the cancer drugs fund, which I think is important. About 150 of my constituents will die from cancer this year—about 100,000 people a year. Currently, 15% of 15-year-olds are regular smokers. Does my hon. Friend feel, as I do, that we should have standardised plain packaging of cigarettes to discourage the take-up of smoking and the cancer that results from it?

[Pauline Latham]

I certainly do, and having watched my mother die from lung cancer, I passionately believe in anything that will stop people smoking. It is not a pretty sight, and I would do anything to stop young people in particular taking up the drug of smoking. That is important.

[Sir Gerald Howarth]

I am grateful to my hon. Friend for giving way. Our hon. Friend the Member for Thurrock (Jackie Doyle-Price) mentioned the risk from counterfeit tobacco, which is very serious indeed. There are two risks: first that the substance will be less pure than commercial tobacco; and secondly that the Treasury will lose a tremendous amount of money as the result of trafficking.

[Pauline Latham]

There is already counterfeit tobacco, so I do not see that it would make much difference. Those who are drawn to smoking do not go over and buy counterfeit goods; they start off in this country—often under age—by buying cigarettes over the counter. If we can stop that, I passionately believe we should do so, and I am disappointed that that measure was not in the Queen’s Speech.

The cancer drugs fund is a force for good, but in my constituency of Mid Derbyshire, which was covered by the east midlands cancer drugs fund, I have had constituents who were unable to access cancer drug treatment that was available from other CDFs. In one case, if my constituent had lived just 40 minutes down the road in Burton upon Trent in the west midlands, that CDF would have paid for her treatment. She paid more than £60,000 of her own money, but since I first raised the issue she has sadly died. The reforms introduced by the Government from 1 April this year and the establishment of the national CDF will end the unfair system of the postcode lottery. Under treatments now offered by the new NHS Commissioning Board, if my constituent were alive today, she would have access to that treatment.

[Hugh Bayley]

Will the hon. Lady give way?

[Pauline Latham]

I am running short of time; I am sorry but I must make progress.

I urge my right hon. and hon. Friends on the Front Benches to look again at this matter because the Government have set up the CDF to ensure that people get access to the life-saving cancer treatment they need. I have constituents who need access to a form of radiotherapy called “SIR-Spheres”, which is used where bowel cancer has spread to the liver. That treatment is not now available anywhere in the NHS—people can pay for it, of course—although it was previously available in most CDF areas, although not the east midlands. Will the Minister look again at the issue and meet me and my constituents’ hospital consultant, Dr Jamie Mills, to see whether we can make progress?

I recently started working with the British Heart Foundation on sudden adult death syndrome after I was contacted by two constituents whose son, Sam, died suddenly as a result of cardiac arrest. He was 19 years old. SADS claims the lives of at least 12 young people such as Sam every week, but many of those fatalities are completely preventable. I knew a young man in his 20s who died in the middle of his round in a dressage competition. Like Sam, he was a very fit young man. All such young deaths are devastating for everyone concerned, family and friends alike.

The seconds and minutes after someone has a cardiac arrest are vital to ensuring their survival. Cardiopulmonary resuscitation should be used immediately until a defibrillator can be located. If those activities are used together, the potential for survival is immediately increased. In fact, here in the UK, we currently have only a 20% survival rate—that figure is for all cardiac arrests, not just cardiac arrests among young people—but in Seattle, where there is mandatory CPR education in secondary schools, the survival rate has increased to 54%. I am sorry that my hon. Friend the Under-Secretary of State for Skills in the Department for Education is no longer in the Chamber—he was here a few minutes ago. My suggestion is that, if we roll out a schools programme, we could increase survival rates, as more children are trained to undertake CPR and to follow-up with defibrillators.

I am deeply concerned about those figures. I should like to highlight the pressing need for the availability of life-saving equipment and skills in our schools. In the first instance, will the Department of Health work with local authorities through health and wellbeing boards to urge them to consider providing funding to install automated external defibrillators in all schools and other local authority facilities? AEDs are very simple to use, even for the untrained layperson. Detailed instructions on how they are to be deployed are delivered through a set of simple audio and visual commands. The machines are programmed to administer an electrical shock only if the patient’s condition requires it. In order to prevent mortality as a result of SADS, it is essential that those easy-to-use and relatively inexpensive devices are made available in schools.

Further to the availability of AEDs, it is also extremely important that, through citizenship lessons, children of school age are aware of, and able to administer, life-saving treatment such as CPR. Such a scheme would cost local authorities very little, and ultimately has the potential to save many lives every year. Organisations such as St John Ambulance would be able to go to schools to train students and teachers so that they are able to undertake such treatment.

In addition, I should like to point out to hon. Members that the British Heart Foundation provides grants to schools for defibrillators. Many schools are not aware of that. Perhaps MPs on both sides of the House could make schools in our constituencies aware of the grant. I look forward to working with the Department of Health on the issues that I have raised about the cancer drugs fund and on defibrillators.

[Steve McCabe (Birmingham, Selly Oak) (Lab)]

It is a pleasure to follow the thoughtful speech of the hon. Member for Mid Derbyshire (Pauline Latham).

I congratulate the Government on their fine display of unity on the Queen’s Speech. In all my years in the Whips Office, I cannot recall seeing anything quite like it. In the early days of the Government, the ambition was simple: wipe out the deficit in a single Parliament, set debt on a downward path and restore health to the economy. Hon. Members were to judge success by how the credit ratings agencies maintained the triple A rating. Simple! The Government now claim that their ambition is to cut the deficit by a third, but almost everyone else believes it is more likely to be cut by only a quarter. That is our lot for the rest of the Parliament. Debt is rising, not falling, and triple A credit ratings are but a distant memory.

After the costs in administrative chaos caused by the top-down reorganisation of the health service, which the Prime Minister promised would not happen, the Government are turning their hand to social care. They are right to do so, at least in the sense that social care is a time bomb that desperately needs tackling. My most recent survey of constituents in Selly Oak shows that 73% of them consider care to be an issue of extreme importance, and only 42% think that the quality of care received by someone close to them is satisfactory.

People are struggling—people such as Mrs Hanslow, who cares for her 96-year-old father. She asks only for the odd break, and in the past she has arranged that by phoning a social worker. When she tried that this February, she discovered that the social worker had left. The office said that somebody would phone her back, but nobody did. She phoned again and was told that she needed to make a fresh application; apparently, files and arrangements leave with the social workers these days.

After several abortive attempts, Mrs Hanslow spoke to a nice lady called Wendy, who said that she would sort the situation out. Then a Mrs Collins rang saying that she was arranging for a social worker to come. But guess what? Mrs Hanslow waited in all day and no one came. Frustrated, she rang again and spoke to a Jackie, who could find no record of her application or complaint but said that someone would ring her back. No one rang, so Mrs Hanslow phoned again. This time, people at the office were not so nice. Mrs Hanslow was told that nothing had been reported because the social worker was out of the office.

[Pauline Latham]

What the hon. Gentleman is describing is the fault of the local authority, not the Government. The local authority is responsible for social workers, not the Government.

Childhood Obesity and Diabetes

Pauline Latham Excerpts

Wednesday 24th April 2013 Westminster Hall

[Keith Vaz]

My hon. Friend is absolutely right. I hope that by securing the debate and by hearing the contributions of hon. Members, we can get a pathway to try and show that complacency will actually help people to get diabetes. That is why I hope that hon. Members will join me today in a war on sugar, a fight against fat, and a battle against the bulge.

We must address three key areas. The first is the role of Government in facing the obesity epidemic head on. That is closely linked to the second key area, which is the role of food and drink manufacturers. The responsibility deal was a flagship of the previous Secretary of State for Health, who is currently Leader of the House. It was launched in March 2011, but I am sorry to say, it appears to have failed. Voluntary agreements with industry have made little impact. The headline pledge to cut 5 billion calories a day is simply incalculable, arbitrary and misleading.

The Department of Health, in response to a parliamentary question of mine, said:

“It is not possible to measure the exact contribution of business’ actions to changes in consumers’ calorie consumption.”—[Official Report, 6 February 2013; Vol. 558, c. 339W.]

By February 2013, 122 companies had signed up to one or more of the responsibility deal’s six pledges, but it is what happens afterwards that really matters. Those pledges, sadly, in my view—I am ready to be convinced otherwise when the Minister replies—have, at best, paid lip service to the Government’s aim of getting the nation to eat more healthily, drink less, be more active, and have healthier working lifestyles.

[Pauline Latham (Mid Derbyshire) (Con)]

Does the right hon. Gentleman agree not only that parents have a huge responsibility to feed their children appropriately and ensure that they get adequate exercise, but that schools have a huge responsibility to give children nutritious, non-fattening and not sweet foods—healthy foods—and through sports, encourage them to take the exercise that will make them healthy and set in train for their whole lives the habits of exercising and eating healthily? It is not only about parents, because schools should help too, as well as the industry that he is talking about.

--- Later in debate ---

[Keith Vaz]

I thank my hon. Friend for her intervention. I did not know that that was the case, but if it is, it should be put right. All teaching establishments should be treated on the same basis and should all get the same message from Government.

Let us consider the issue of where schools are situated and the ability of fast-food chains to mushroom around schools. Many children purchase fast food on their way home from school. For many, fast food is readily available. For example, in my constituency, there are 61 fast-food outlets within a 1-mile radius of Rushey Mead primary school. Positive action has been taken by some local authorities. Waltham Forest council, for example, banned fast-food outlets near schools in 2008. However, more must be done to address the issue. Since 1 April 2013 and the creation of health and wellbeing boards, the onus has surely been on local councils to consider sensible planning restrictions to tackle childhood obesity.

Schools need to do more to educate pupils about the benefits of eating a healthy diet. I commend the excellent report by Ella’s Kitchen, “Averting A Recipe For Disaster”, which urges the Department for Education to address poor nutrition for children by making cooking in schools compulsory and by giving free breakfasts to every child. We currently have an epidemic of childhood obesity, which in 20 years’ time will turn into an epidemic of type 2 diabetes.

The incidence of diabetes is truly alarming. Sometimes we repeat these statistics so often that they lose their impact, but I have to repeat them again today. There are an estimated 3 million people in the UK with the condition, and a further 850,000 are thought to have the condition but are not aware of it. The complications from poorly managed and poorly treated diabetes are shocking. It is the leading cause of blindness, kidney failure and lower-limb amputations. Each week, there are 100 diabetes-related amputations; and each year, 24,000 people die earlier than expected due to complications from the condition. Not only are the health risks extreme, but the cost to the NHS is enormous. It is astonishing. The NHS spends roughly £9.8 billion a year and 10% of its budget treating the condition and its associated complications.

[Pauline Latham]

The right hon. Gentleman talks about amputations. My father had his leg amputated because of diabetic complications, but his problem was that he never stuck to his diet. People must be given more help to understand the complications that they can and probably will incur if they do not take the prognosis seriously and control their diet, because if they do not do so, they will have those long-term problems.

[Keith Vaz]

The hon. Lady is absolutely right. I do not want to steal lines from the Minister’s speech, but when she recently addressed a forum on diabetes, that was exactly what she said: diet is extremely important. We are all busy people and when we walk into the Tea Room for our cup of tea, we are faced with Club biscuits, Jaffa Cakes, Victoria sponges—plural—and all kinds of other things that entice us, so even if I go in saying that I must have a banana or an apple, I end up, as the hon. Member for Strangford has seen, picking up a Club biscuit. The hon. Member for Mid Derbyshire is absolutely right: diet is crucial. That is why I wish the newly appointed diabetes tsar, Dr Jonathan Valabhji, the best of luck in dealing with those figures.

How do we cope with this situation? There are practical steps that health care providers, local authorities and the general public can take, but the key is prevention. The new NHS health checks will offer those aged between 40 and 74 a check to assess their risk of heart disease, stroke, kidney disease and diabetes. If only I had had that check when I was 40, I would have discovered six years earlier that I had diabetes. However, new research revealed by the university of Leicester on Friday suggests that the checks could detect at least 158,000 new cases of diabetes or kidney disease, but they are not being taken up. I pay tribute to the work of Professor Kamlesh Khunti of Leicester university, who was behind the research that revealed the number of cases that could be discovered. The health check has enormous potential to find those in the early stages of diabetes or even with symptoms of pre-diabetes.

Oral Answers to Questions

Pauline Latham Excerpts

Tuesday 15th January 2013 Commons Chamber

[Mr Hunt]

Of course, I understand the concerns of Cancer Research, and I know that the hon. Gentleman understands the personal tragedy that cancer can cause. The change in the clinical networks is happening because we want them to cover dementia, which we were talking about earlier, mental health services and maternity and paediatric services. It is right that they should do so, but I want to make absolutely sure that as we go through the restructuring the benefits of the cancer clinical networks remain as strong as ever.

[Pauline Latham (Mid Derbyshire) (Con)]

Will my right hon. Friend look at the east midlands cancer drugs fund? While I welcome the cancer drugs fund enormously, the east midlands will yet again underspend, leaving some of my constituents paying for their own treatment because they have been refused funding. Will my right hon. Friend please get his Department to investigate why?

[Mr Hunt]

My hon. Friend has mentioned the issue to me before, and I am happy to look into it in detail for her.

Oral Answers to Questions

Pauline Latham Excerpts

Tuesday 27th November 2012 Commons Chamber

[Dr Poulter]

We have had encouraging results from national pay negotiations at the recent NHS Staff Council, and unions are to consult their members on those results. There is general agreement that we need to maintain national pay frameworks, provided they are fit for purpose. I hope my hon. Friend will find that the south west pay consortium, which has been somewhat heavy-handed in the way that it has conducted its affairs, also sees the benefit of maintaining national pay frameworks. That is why we would like to see a quick resolution of the matter at a national level.

[Pauline Latham (Mid Derbyshire) (Con)]

6. What recent assessment he has made of the cancer drugs fund.

[The Secretary of State for Health (Mr Jeremy Hunt)]

Since October 2010, more than 23,000 patients in England and more than 1,600 patients in NHS East Midlands have benefited from the additional £650 million funding for cancer drugs that this Government have committed to providing.

[Pauline Latham]

I thank my right hon. Friend for that answer, but I have previously raised in the House a constituency case where the NHS East Midlands cancer drugs fund would not pay for drugs that other CDFs would pay for, such as Avastin for second-line treatment of bowel cancer. Sadly, my constituent has since died because she could not get funding for the drugs she needed, having spent all her own money funding the treatment herself. Will my right hon. Friend meet me and my late constituent’s consultant, Dr Bessell, to discuss how we can end this postcode lottery?

[Mr Hunt]

Proud as we are of the cancer drugs fund, to hear such stories is extremely distressing, and our first thoughts are with the family of my hon. Friend’s constituent. We will of course look into the issue she raises, which is a cause of great concern. I know that the Under-Secretary of State for Health, my hon. Friend the Member for Broxtowe (Anna Soubry), is a neighbouring MP and would be happy to meet her to discuss the matter.

Children’s Cardiac Surgery (Glenfield)

Pauline Latham Excerpts

Monday 22nd October 2012 Westminster Hall

[David Tredinnick]

My hon. and learned Friend says I can make an exception for him, and I am delighted to do that.

The first point I want to make is that there is real concern that we are working on faulty statistics. The data used to make the decision were based on 2006-07. We need only consider the recent publication of the census in London to see the huge increase that there has been in population. There are shifting populations, and there is concern that the analysis is fundamentally flawed. It is not only my right hon. Friend the Secretary of State for Health who has had to consider flawed data recently. What about the west coast main line, whereby we found we were operating with completely inaccurate information? The right hon. Member for Newcastle upon Tyne East (Mr Brown) nods his head. This can happen in Departments, and we must take note of it.

My hon. and learned Friend the Member for Harborough and the hon. Member for Leicester South have addressed the issue of the ECMO link. To most reasonable people, it seems absurd that the two decisions will not be linked. I am sure that there are legal arguments, but somehow we must get a sensible decision so that both issues can be considered together.

The next point concerns the site of Glenfield. Glenfield is a hugely popular hospital not just with patients, but with surgeons. From, one might say, a feng shui point of view, it is on top of a hill outside the city, and it has a good, clean, clear energy. That is why everybody likes working there: it is nicer for everybody than the Birmingham site, as is proven, I would suggest, by a survey showing that only 2% of the staff in Glenfield want to move to Birmingham. It is not just BBC current affairs programmes that are jumpy about moving out of their current locations, as there is a real problem with the decision to move from Glenfield to Birmingham, as the hon. Member for Leicester South said. The body of knowledge built up over 20 years will dissipate, because many of the people who work at Glenfield simply will not move.

My next point involves the increased pressure on Birmingham, which has been referred to. Can Birmingham deal with it? Somewhere in the briefing papers is a point about Bristol. What happens if something goes wrong at Bristol and patients are moved around? My hon. and learned Friend the Member for Harborough made the point about the terrible tragedy in Wales, during which patients have been brought to Glenfield. Is it wise to concentrate all the resources in the midlands in one centre? I wonder whether it is.

[Pauline Latham (Mid Derbyshire) (Con)]

Birmingham is already having to send patients to Glenfield because it cannot cope with the numbers. Does my hon. Friend not agree that it seems silly to close such a popular centre? As he said, there will be a knock-on effect if other centres close, but patients are already being sent from Birmingham to Glenfield, and children are being sent to different hospitals because there is no room at Birmingham. It seems absolutely crazy that my constituents cannot continue to use the Glenfield hospital, where so much expertise has been created over a number of years.

[David Tredinnick]

I agree absolutely with my hon. Friend, who makes another valid point.

I will not detain the House for long, as other hon. Members want to speak, but I want to make two more points. I have had letters from all over my constituency from people who have benefited from Glenfield. Let us think for a moment. Who put the money into the unit in the first place? Was it all Government money? No, it was not. A lot of charities in Leicestershire have raised money to support the unit. What about their efforts? How will they feel, having struggled over the years to provide a superb local service? It will be a great injustice if that money is dissipated in a reorganisation.

I am delighted to see my hon. Friend the Minister in her place, and I congratulate my hon. and learned Friend the Member for Harborough and all the other Leicestershire Members, including my hon. Friend the Member for Loughborough (Nicky Morgan) and the hon. Member for Leicester West (Liz Kendall), across the Floor, who has worked on the issue. I say to my hon. Friend the Minister that this is a critical problem. Please help us.